TO’s capability for regulating SREBPAc, PGC1-α, and PGC1-β expression implies the preventive action of the oil for insulin resistance, type II diabetes, and diabetic dyslipidemia since PGC1-α promotes hepatic gluconeogenesis, PGC1-β stimulates SREBPAc expression, and SREBPAc endorses de novo hepatic lipogenesis [30,31]. This evidence concerns the gene PPARGC1A and type 2 diabetes mellitus.